

COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis.

Clio Bilotta^{1*}, Giulio Perrone², Valeria Adelfio³, Giovanni F. Spatola⁴, Maria Laura⁴, Antonina Argo¹, Stefania Zerbo¹

¹Section of Legal Medicine, Department of Health Promotion, Maternal-Infant, Internal and Specialized Medicine of Excellence G. D'Alessandro, University of Palermo, Italy, ²Section of Legal Medicine, department of Health Promotion, Maternal-Infant, Internal and Specialized Medicine of excellence G. D'Alessandro, University of Palermo, Palermo, Italy, ³Department of Economics, Business and Statistics, University of Palermo, Italy, ⁴Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Italy

Submitted to Journal:
Frontiers in Immunology

Specialty Section:
Vaccines and Molecular Therapeutics

Article type:
Systematic Review Article

Manuscript ID:
729251

Received on:
22 Jun 2021

Revised on:
03 Nov 2021

Journal website link:
www.frontiersin.org

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

Clio Bilotta and Giulio Perrone set the systematic review, selected and analysed data and wrote the results and discussion. Valeria Adelfio processed statistical data and wrote statistical results. Stefania Zerbo and Antonina Argo reviewed the selected data and wrote discussion and conclusion. Giovanni Francesco Spatola and Uzzo Maria Laura analysed clinical and histopathological data. All authors contributed to the article and approved the submitted version.

Keywords

Covid19 vaccine, vaccine-related thrombosis, vaccine adverse effects, Vaccine complications, PF4 antibodies

Abstract

Word count: 349

Introduction: The World Health Organization declared the COVID-19 pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA. Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients' features, potential pathophysiologic mechanisms, timing of appearance of the adverse events, and other critical issues.

Methods: Two authors performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed database and through manual searches. We selected 10 out of 49 articles and performed a descriptive analysis of the adverse events caused by the mRNA-based vaccines as well as the adenovirus-based AstraZeneca vaccine.

Results: In the articles on the Pfizer and Moderna vaccines, the sample consisted of three male patients. The time from vaccination to admission was ≤ 3 days in all cases; all patients presented signs of petechiae/purpura at admission, with a low platelet count. In the studies on the AstraZeneca vaccine the sample consisted of 58 individuals with a high female prevalence. Symptoms appeared around the 9th day, and headache was the most common symptom. The platelet count was below the lower limit of the normal range. Almost all patients were positive for PF4 antibodies. The cerebral venous sinus was the most affected site. Death was the most prevalent outcome in all studies.

Discussion: Vaccine-induced thrombotic thrombocytopenia (VITT) is an unknown nosological phenomenon secondary to inoculation with the Covid-19 vaccine. Recent studies have assumed a physiopathological mechanism that is assimilable to heparin-induced thrombocytopenia, with protagonist antibodies against the PF4-polyanion complex. Viral DNA has a negative charge and can bind to PF4, causing VITT. New experimental studies have hypothesized that thrombosis is related to a soluble adenoviral protein spike variant, originating from splicing events, which cause important endothelial inflammatory events.

Conclusion: Further studies are needed to better identify VITT's pathophysiologic mechanisms and genetic, demographic, or clinical predisposition of high-risk patients; to investigate the correlation of VITT with the different vaccine types; and to test the significance of the findings.

Contribution to the field

This work aims to give a contribution to the recent literature debate about anti-Covid19 vaccines-related thrombosis. We analyzed all the available data to better understand the pathophysiologic mechanism, genetic, demographic or clinical predisposition outlining the high-risk subjects, the correlation with the different vaccine types and test the significance of findings. We would highlight the high heterogeneity of the data collection with lack of important findings hindering the statistical analysis and the complete understanding of this phenomenon. We encourage a more complete data collection for future studies.

Funding statement

this research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors

Data availability statement

Generated Statement: The authors acknowledge that the data presented in this study must be deposited and made publicly available in an acceptable repository, prior to publication. Frontiers cannot accept a manuscript that does not adhere to our open data policies.

In review

COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis.

Running title: COVID-19 vaccine-related thrombosis

Authors Name and Academic Degrees:

Clio Bilotta MD^{1†} & Giulio Perrone MD^{1†}, Valeria Adelfio², Giovanni Francesco Spatola PhD³, Uzzo Maria Laura MD³, Argo Antonina PhD¹, Zerbo Stefania PhD¹

Authors' Affiliations:

¹ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Section of Legal Medicine, University of Palermo, Italy.

² Department of Economics, Business and Statistics, University of Palermo, Italy.

³ Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University of Palermo.

Corresponding Author:

Clio Bilotta MD¹

Via del Vespro 129, 90127 Palermo, Italy

Phone: +39.091.655.2424, +39.349.05.30.138; Fax: 0916553203 Email: cliobilotta89@gmail.com

Keywords: COVID-19 vaccine; vaccine-related thrombosis; vaccine adverse effects; vaccine complications: PF4 antibodies.

Number of words: 3,518

Number of figures and tables: 8 figures/7 tables

Contribution to the Field Statement:

This work aims to contribute to the recent literature debate on Coronavirus Disease-19 COVID-19 vaccine-related thrombosis. We analyzed the available data to better understand the pathophysiologic mechanism and genetic, demographic, or clinical predisposition in the high-risk individuals, to allow investigation of potential correlation between thrombosis and two different vaccine types, and to test the statistical significance of the findings. We discuss the high heterogeneity of the collected data, and a lack of statistical power in certain important findings which hinder complete understanding of this phenomenon. More future studies are needed to draw more robust conclusions.

Abstract

Introduction: The World Health Organization declared the COVID-19 pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA.

Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients' features, potential pathophysiologic mechanisms, timing of appearance of the adverse events, and other critical issues.

Materials and Methods: Two authors performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed (MEDLINE) database and through manual searches. We selected 10 out of 49 articles from January 1 to May 5, 2021 and performed a descriptive analysis of the adverse events caused by the mRNA-based Pfizer and Moderna vaccines as well as the adenovirus-based AstraZeneca vaccine.

Results: In the articles on the Pfizer and Moderna vaccines, the sample consisted of three male patients with age heterogeneity. The time from vaccination to admission was ≤ 3 days in all cases; all patients presented signs of petechiae/purpura at admission, with a low platelet count. In the studies on the AstraZeneca vaccine the sample consisted of 58 individuals with a high age heterogeneity and a high female prevalence. Symptoms appeared around the 9th day, and headache was the most common symptom. The platelet count was below the lower limit of the normal range. All patients except one were positive for PF4 antibodies. The cerebral venous sinus was the most affected site. Death was the most prevalent outcome in all studies, except for one study in which most of the sample is alive.

Discussion: Vaccine-induced thrombotic thrombocytopenia (VITT) is an unknown nosological phenomenon secondary to inoculation with the Covid-19 vaccine. Several hypotheses have been formulated regarding its physiopathological mechanism. Recent studies have assumed a mechanism that is assimilable to heparin-induced thrombocytopenia, with protagomist antibodies against the PF4–polyanion complex. Viral DNA has a negative charge and can bind to PF4, causing VITT. New experimental studies have assumed that thrombosis is related to a soluble adenoviral protein spike variant, originating from splicing events, which cause important endothelial inflammatory events, and binding to endothelial cells expressing ACE2.

Conclusion: Further studies are needed to better identify VITT's pathophysiologic mechanisms and genetic, demographic, or clinical predisposition of high-risk patients; to investigate the correlation of VITT with the different vaccine types; and to test the significance of the findings.

Manuscript:

1 Introduction

The World Health Organization declared the COVID-19 pandemic on March 11, 2020 (1). SARS-CoV-2, the pathogen causing this infection, has a mortality rate of 2.3% (China) to 7.2% (Italy) and high transmissibility (2, 3). Globally, as of June 15, 2021, there have been 176,156,662 confirmed cases, and among them, 3,815,486 deaths have been reported (4). SARS-CoV-2's viral characteristics together with globalization of the infections have considerably reduced the possibility of infection containment despite various preventive measures implemented by different governments worldwide. The acceleration of COVID-19 vaccine development has become necessary due to this global state of emergency (5). A few vaccines have been developed and licensed for clinical use in less than one year.

Two such vaccine types were developed using two different technologies: viral vectors, herein adenovirus, and mRNA. Both vaccine types aim to induce an immune response and generation of

neutralizing antibodies against the SARS-Cov-2 spike protein. The spike protein, expressed on the virus surface, enables the virus to bind to human target cells and upon entry to reproduce itself. Viral vector vaccines, such as Vaxzevria (AstraZeneca), exploit a weakened version of chimpanzee adenoviruses rendered able to enter and reproduce itself within human cells. The adenovirus codes for the SARS-CoV-2 spike protein in the nucleus, which upon translation in the cytoplasm and expression triggers an immune response (6, 7). The COVID-19 mRNA vaccines, such as Comirnaty (Pfizer) and mRNA-1273 (Moderna), contain mRNA molecules encoding spike proteins within human cells (8, 9).

As of June 15, 2021, a total of 2,310,082,345 individuals have been vaccinated (4). However, little is known regarding these experimental vaccines, whose phase IV clinical trial is monitored during the current mass vaccination and will be necessary for identifying, cataloging, and quantifying adverse reactions since the large sample size would compensate for the reduction in the experimentation (do you mean the short time it took to develop and license the vaccines) time (10).

Different types of vaccine adverse effects have been described, such as anaphylaxis, fever, joint and muscular pain, headache, weakness, nausea, chills, erythema, lymphadenopathies, paraesthesia, vomiting, dizziness, arrhythmias, changes in blood pressure, and facial paralysis (11). Thrombosis is one of the most severe and nontypical adverse effects. Some authors have hypothesized an incidence of approximately one in 100,000/1,000,000 individuals who received the adenoviral vector vaccine (12).

Our study aimed to analyze literature reports of thrombosis after COVID-19 vaccine administration to identify patients' features, potential pathophysiologic mechanism, timing of adverse events, and critical issues to prevent further deaths adding to those that are COVID-19-related.

2 Methods

Two reviewers performed a systematic electronic search of scientific articles on COVID-19 vaccine-related thromboses and their complications on the PubMed (MEDLINE) database and through manual searches. The obtained results were filtered according to the following criteria: English language and human species. We used the following combinations of key words: "Covid vaccine AND PF4" OR "Covid vaccine AND immune thrombocytopenia". We found a total of 49 results from PubMed and one through manual searches. We initially selected 41 of the 49 articles, analyzing the titles and abstracts, and, where useful, opening and studying articles in full text. According to the following inclusion criteria, we selected 10 articles from January 1 to May 5, 2021 (Figure 1): titles and abstracts related to COVID-19 vaccination and its adverse reactions; full-text articles concerning COVID-19-vaccine related thrombosis and subsequent hospitalization; and articles reporting data on platelet count and anti-PF4 antibodies of affected patients. The exclusion criteria were articles with absence of data or information on vaccine-related adverse effects, management, laboratory tests or treatment and languages other than English.

We analyzed 10 articles (13-22) reporting an overall sample of 61 individuals vaccinated with the AstraZeneca, Pfizer, and Moderna vaccines (Table 1). The mRNA COVID-19 vaccines were administered in a few cases: Pfizer in only one individual (19) and Moderna in two individuals (16, 17). Hence, we performed only a descriptive analysis of the Pfizer and Moderna vaccines. Meanwhile, an exploratory analysis of the AstraZeneca vaccine was performed because of the small sample size to obtain an unbiased statistical analysis.

3 Results

3.1 Pfizer and Moderna

The sample reported in the (state exactly which studies you are referring to. Not clear which three studies are mentioned above) three studies (16, 17, 19) comprised of three men (one patient in each study) with ages 74, 60, and 22 years (median age: 52 years). The time from vaccination to admission was ≤ 3 days in all cases. The total sample of all three studies presented signs of petechiae/purpura at admission. Of the sample, 67% was under antihypertensive therapy. One patient had a clinical history of hepatitis C, chronic heart disease, kidney failure, and immunosuppressive therapy, presenting with a wide range of signs and symptoms, such as chest and abdominal pain, hypertension, dyspnea, nausea, vomiting, and pitting edema.

All three individuals had a platelet count below the lower limit of the normal range (10000, 84000, and 2000) with a median value of 32,000. Only one study (19) specified data on the positivity of platelet antibodies IIb/IIIa and Ia/IIa. Two (16, 19) of the three individuals received corticosteroid therapy, IVIG, and platelet transfusion; one received a thrombopoietin/thrombopoietin receptor agonist (16), and one did not receive treatment (17). No studies described radiological and autopsy findings or thrombosis locations. No deaths were recorded.

3.2 AstraZeneca

We analyzed 58 individuals reported in seven studies (13-15, 18, 20-22).

3.2.1 Demographic characteristics

We explored the demographic characteristics of the sample, although there was a clear limitation in the heterogeneity of the data collection. We decided to report only age range and sex frequencies (Table 4).

The age range is highly heterogeneous and does not allow for the determination of the global range of the sample. The sample showed a high prevalence of the female sex.

3.2.2 Medical history

The medical history of the patients was reported in only 3 studies (13, 15 18). One study (18) had a sample size of a single individual with a medical history characterized by pre-eclampsia and allergies, and another study (15) has reported the prevalence of allergies and an equal distribution of hypertension, asthma, contraception, and hormone replacement therapy (Figure 4).

3.2.3 Temporal relationship

The analysis of the time from vaccination to admission revealed that one study (13) did not report this datum. The two studies (18, 21), with a sample of a single individual, have reported a time distribution of 7 days, while the other studies have reported a range of 8–9 to 16 days (Table 5).

We created a graph for the comparison of densities to better analyze the distributions (Figure 5) as these studies had different densities. We observed that the patients were admitted on the 15th day after the vaccination in the studies with a larger sample size and on the 10th day after the vaccination in the studies with a smaller sample size.

Regarding the onset of symptoms from vaccination, only four studies have reported this datum (13, 18, 20, 21). We could consider only two studies (13, 20) since the other two (18, 21) had a sample of a single case, noticing that the symptoms appeared around the 9th day, with a statistical accuracy of

± 1 , after the vaccination in both studies (Table 6). These results were confirmed by observing the densities (Figure 6). Thus, during the first 15 days after vaccination there is a high risk of developing all adverse symptoms.

3.2.4 Signs and symptoms at admission

Five studies (15, 18, 20, 22) have reported signs and symptoms at admission. We considered the percentage based on the total number of symptoms rather than the number of individuals because of the presence of multiple symptomatology in each individual. We described the two studies separately (18, 21) with a single case as the sample. One study (18) reported a multiple symptomatology consisting of inverted plantar reflex; speech, walking, and movement disorders; hemiparesis; facial paresis; and drowsiness; the other study (21) reported only abdominal pain in a patient. Headache was the most common symptom on admission. The other symptoms had similar proportions (Figure 7).

3.2.5 Platelet count, fibrinogen, and PF4 antibody positivity

The platelet count was below the lower limit of the normal range in each study with different accuracies indicated by the standard error (S.E.) expressing the variation of the average estimate. The absence of S.E. indicates a lack of data in the respective study.

The average fibrinogen level was within the normal range (150–400 mg/dl) in all studies (Table 2). We studied the prevalence distribution of anti-PF4 antibodies, highlighting the complete positivity (100%) of the sample, except for one patient (93%) (Table 3).

3.2.6 Autopsy findings

Most studies did not describe autopsy findings. One study (18) reported a major intracranial hemorrhage in one patient. This complication has also been reported in two other studies (13, 14), one of which (14) had a high heterogeneity describing subarachnoid hemorrhage, myocardial infarction, cerebral and bowel infarction, and adrenal hemorrhage (Figure 2).

3.2.7 Thrombosis location

We examined the proportions of thrombosis location (Figure 3) and performed the calculation based on the number of thromboses rather than the number of individuals. Thrombosis could develop in several blood vessels in each patient exceeding the sample; therefore, the ratio could be >1 .

Only two studies had a sample of 1 patient (18, 21), one of which described a case of internal carotid artery thrombosis, and the other one had a multiple-located thrombosis involving the cerebral venous sinus (CVS), intracerebral, and pulmonary vessels. In the other studies, CVS was the most affected location, with a percentage of 25%–45%. No other proportions were comparable because of their high heterogeneity and small sample sizes.

3.2.8 Treatments

Five studies reported data on hospital treatment (13, 15, 18, 21, 22). We considered the percentage based on the total number of treatments rather than the number of individuals because of the presence of multiple therapies in each individual. We highlighted the absence of a specific treatment prevalence in the overall sample. The analysis of the proportions of single studies indicated that antifibrinolytic treatment was the most commonly used therapy in two studies (18, 22), and corticosteroid therapy in

two other studies (15, 21). Heparin treatment or no medical treatment was the prevalent therapeutic approach in another study (13) (Figure 8).

3.2.9 Outcomes

Five studies (13, 14, 15, 18, 21) specified patient outcomes. Both patients died in the cases described in the two studies with a sample size of a single individual. Death was the prevalent outcome in all studies, except for one study (14) with a reported survival rate of 70% (Table 7).

4 Discussion

The current mass vaccination led to the discovery of vaccine-induced thrombotic thrombocytopenia (VITT), an unknown nosological phenomenon secondary to the inoculation of the COVID-19 vaccine (13, 14, 15, 18, 21). The pathophysiological mechanism behind this adverse reaction remains unclear. Recent studies have assumed a mechanism that is similar to heparin-induced thrombocytopenia (HIT) (13). The latter represents a known adverse reaction that remains one of the most serious complications in individuals treated with heparin (23). A platelet count decrease of >50% and a procoagulant state with a secondary development of venous or arterial thrombosis represents the main diagnostic criteria from a clinical laboratory point of view (24).

There may be an immune-mediated mechanism at the root of thrombosis, with protagonist antibodies against the PF4–polyanion complex. VITT associated PF4 antibodies interact with the heparin-binding site. These antibodies are therefore independent from heparin. The immune complexes, formed from the binding of PF4 to antibodies, activate platelets through Fc γ RIIa receptors, causing thrombocytopenia and thrombosis secondary to the activation of the coagulation pathway. Therefore, *in vitro*, heparin does not increase the activation of platelets in case of thrombosis with thrombocytopenia syndrome (TTS); heparin could inhibit platelets' activation secondary to a pharmacological antagonism. The independence from heparin denotes a similarity between TTS and HIT due to heparin-independent antibodies; the main differences consist of the needed previous exposure to heparin in HIT and its greater incidence rate than VITT. The antibodies of HIT heparin-independent and TTS have a high affinity for the receptor, and are able to bind it in the absence of heparin. Previous studies discovered that HIT heparin-independent antibodies can activate platelets in the presence of adenoviral vector and in a dose-related manner. In fact, HIT is also caused by various mechanisms, which include polymorphism of Fc γ RIIa receptor (25), monocyte activation, production of tissue factor (26) and generation of procoagulant microparticles (27). These findings suggest the PF4 antibodies-mediated platelet activation may not be the only cause for thrombosis in VITT (13). In fact, polyanions including nucleic acids and components of the bacterial cell wall, with their negative charge, promote binding to PF4, a positively charged chemokine released by platelets during platelet activation (28). It is plausible that the adenoviral SARS-CoV-2-specific proteins could trigger the immunopathological mechanism in VITT, otherwise other DNA-based vaccines may also cause thrombosis. Antibody cross reactivity through molecular mimicry between spike proteins and PF4 epitopes has been hypothesized, albeit not yet proven (29). Regarding nucleic acids, binding with PF4 occurs when their plasma concentration exceeds the normal upper limit of \approx 200 ng/mL (30). The viral DNA has a negative charge and can bind to PF4, acting as an adjuvant because of its phosphate groups which can stimulate Toll-like receptor (TLR)-9 on plasmacytoid dendritic cells with the subsequent production of interferon (IFN) alpha (31). RNA is also negatively charged;

therefore, it has not been entirely excluded as a cause of cascade of pathological events. The local concentration of nucleic acids increases due to their release by specific cell structures under particular conditions, such as the breakdown of viral and bacterial pathogens, massive tissue damage, and increased apoptosis (32-34). Several authors have reported a correlation between this pathologic event and bacteremia, even when it is subclinical, as in the case of periodontitis. (33). Other authors have also recently highlighted the viral capacity to trigger this pathological process (35-36). Moreover, major surgeries, such as knee replacement, may constitute another risk factor (37-40). New experimental studies on vaccine-related thrombosis have recently been performed, suggesting a new possible mechanism (41). They assumed that thrombosis is related to a soluble adenoviral protein spike variant, originating from splicing events, which cause important endothelial inflammatory events, binding to endothelial cells expressing ACE2. This mechanism may also be related to severe cases of SARS-Cov-2 and pseudovirus infections. This would explain the greater correlation of thrombosis with the adenovirus-based rather than with mRNA-based vaccines.

It is also possible there is a common physiopathological mechanism for COVID-19 infection and VITT or HIT. Some researchers hypothesized an important role of the innate immune system in causing thrombotic events in COVID-19 patients, as well as in cases of VITT or HIT (42).

Neutrophils, which are cells of the innate immune system, are able to capture microorganisms through neutrophil extracellular traps (NETs), that are essential structures for phagocytosis. Dysregulation of this mechanism is responsible for the procoagulant state and the subsequent alveolar damage and coagulopathy of COVID-19 patients (43).

Inflammation and infection are known to stimulate neutrophil recruitment (44). Excessive activation of neutrophils in CoVID-19 patients could therefore trigger the coagulopathy secondary to the fibrin deposition during phagocytosis (45).NETs' components, such as cell-DNA, histones and tissue factor (III) can activate the coagulation. The histones stimulate activation of platelets and endothelium interacting with Toll-Like Receptor (TLR) 2 and 4 (46-48); on the other hand, platelets induce NETs' production through P-selectin (49). The NETs expulsion facilitates adhesion and further activation of platelets leading to a self-perpetuating process. Finally, the deposition of fibrin, secondary to NETs, traps bloodstream cells, such as platelets and red blood cells, providing a basis for blood clot formation (49,50).

In case of VITT the certain inflammatory vaccine adjuvants and delivery systems could trigger immune system cells' recruitment, especially neutrophils, through the activation of NPL3 inflammasome and enhance NET production (51-52, 42). NETs' components by binding to PF-4 determine the production of antibodies against PF-4 polyanionic complexes.

(The following sentence does not make sense!! Please clarify. Do you mean either innate or adaptive immunity may cause thrombosis?)As concerns the immunological mechanism, it has been hypothesized as either an innate or humoral mediated response, through the activation of B and T cells, could take part in the pathophysiological mechanism of thrombosis(53-55).

It is assumed that genetic predisposition is based on HIT. Some authors have shown a higher frequency of T-cell death-associated gene 8 (TDAG8) regarding genetic predisposition (56).

Other researchers identified individuals with the Fc γ RIIA-131RR genotype as a susceptible population as they could be more efficiently able to activate a procoagulation response by the activation of platelets and monocytes (57-58).

Therefore, it has been further suggested that monocytes precede the activation of platelets: Fc γ RIIA receptor triggers a downstream response involving tyrosine kinase-dependent pathway, with a subsequent release of thrombin and tissue factor, which are both coagulation promoters (59).

To date, a correlation of VITT with a specific medical history remains unknown.

Interestingly, in our study, the overall patient samples consisted of men in the articles on the Pfizer and Moderna vaccines, while the patient samples were predominantly female in the articles on the AstraZeneca vaccine. These findings should also be further analyzed to evaluate their significance in larger sample sizes.

The diagnostic criteria of VITT are the following: time of onset ranging from 4 to 30 days after the AstraZeneca or J&J administration, diagnosis of thrombosis, finding of thrombocytopenia, and PF4 HIT ELISA positivity.

The evaluation of the increase in anti-PF4 antibodies in VITT is performed differently than that of HIT because of the absence of hospitalization and monitoring of laboratory parameters after vaccination. Consequently, the increase in antibodies in VITT can be evaluated indirectly by analyzing the time relationship between vaccination and the onset of symptoms. This temporal range is similar to that of HIT in our study, which is in accordance with the literature (23).

The anti-PF4/heparin antibody titers, in fact has a characteristic temporal pattern: they appear 4–5 to 10–12 days after heparin administration (60) and disappear within 100 days (61). We noticed that symptoms appeared on the 8th to 10th day after vaccination. We can conclude that during the first 15 days after the vaccination the vaccinees are at high risk of symptom development, and this period may represent the ideal temporal range in thrombosis prevention. Laboratory data monitoring should therefore preferentially be performed in this temporal range.

Based on our study, the most affected thrombosis site was the cerebral venous system and this is confirmed by the observations in the literature (23), which also points out frequent involvement of the portal circulation. In fact, the portal circulation and the cerebral venous circulation drain the intestines and nasal sinus respectively, both sites with a high bacterial presence; it facilitates the passage of bacteria, viral products or toxins in the veins. The interaction between these elements with PF4 could cause an abnormal immune response with platelet and neutrophil activation, in case of high anti-PF4 antibodies titer (23). According to another recent hypothesis, the major incidence of thrombosis in these venous sites could be related to a non-unidirectional blood flow due to body posture in this vascular district, which does not present a valvular system, with a prolonged exposure to the soluble spike protein and a high risk of binding of this protein to endothelial cells expressing ACE2 (41). These sites are different than those affected in the HIT, including adrenal hemorrhagic necrosis, limb thrombosis, disseminated intravascular coagulation, skin necrosis, deep vein thrombosis, left ventricle thrombosis, and endograft thrombosis (62-69).

Cerebral venous sinus thrombosis (CVST) represents a rare pathological disease occurring secondary to blood clots, which obstruct the blood flow of cerebral vessels or dural sinuses (70).

Women of child-bearing age are the most affected subjects (71-72). The major risk factors are anticoagulation therapy, brain infections, head trauma, pregnancy and contraception (73-74). COVID-19 patients presented relatively low incidence of this complication. Recently, some individuals, especially women aged between 18 and 60, developed CSVT after vaccinations with the AstraZeneca and Johnson and Johnson (Ad26.COV2.S) vaccines. The occurrence of these

complications temporarily prohibited administration of the J&J vaccine, in USA and Germany, and of AstraZeneca vaccine in many European countries (75).

The mRNA vaccines, on the other hand, are not associated with this complication (76). CSVT incidence rate hovers around 3-4 cases per million before COVID-19 vaccinations (77). The incidence rate of CSVT is 1 in 100.000 after AstraZeneca and 1 in 1.000.000 after J&J and vaccinations (78).

Clinical presentation includes headache, generalized or localized, in association with hemiparesis and aphasia. Seizures and encephalopathy appear in a minority of such cases, and intracranial hypertension is responsible for their onset .

Secondary symptoms therefore include dyspnea, limbs' weakness, petechiae and lethargy (76).

Randomized controlled trials recommended anticoagulation therapy, except for heparin, in order to avoid the extent of the hemorrhage (77-78). In fact, heparin and heparin-containing products are not recommended due to the risk of progression of thrombosis and the correlation with HIT for the above-mentioned reasons (13).

Some authors propose the administration of plasma exchange, in order to increase the fibrinogen level, or even the use of Bruton tyrosine kinase (Btk) inhibitors. Btk inhibitors could block downstream pathway of FcγRIIA receptor and prevent monocytes and platelets' activation and NETs' formation (79).

Finally, the outcome of VITT depends on the extent of venous, arterial, or microcirculatory thrombotic complications (80-81). We highlighted a negative outcome in all studies reporting these data, except for the largest study with a prevalent positive outcome.

Specific guidelines could be created on the basis of the event's frequency and the eventual risk of revealing patient identity, similar to those for HIT, recommending close monitoring of at risk patients, every 2–3 days, especially during the above-mentioned time interval of the first 15 days after vaccination (83-84).

Further studies are needed to better identify VITT pathophysiologic mechanisms, the importance of genetic, demographic or clinical predisposition, the characteristics of high-risk patients, the correlation of thrombosis with the different vaccine types, and the statistical significance of the findings.

4.1 Study limitations

The small sample size and heterogeneous data collection allowed us to perform an exploratory and descriptive analysis, and hence not testing the statistical significance of the findings.

5 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

6 Availability of Data and Materials

The datasets of the current study are publicly available.

7 Author Contributions

C.B. and G.P. set the systematic review, selected and analyzed data, and wrote the results and discussion. V.A. processed the statistical data and wrote the statistical results. S.Z. and A.A. reviewed the selected data and wrote a discussion and conclusion. G.F.S. and U.M.L. analyzed the clinical and histopathological data. All authors contributed to the manuscript and approved the submitted version.

8 Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

9 Acknowledgments

We would like to thank Editage by Cactus for English language editing.

References

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed.* (2020) 91(1):157-160. doi: 10.23750/abm.v91i1.9397
2. Vermund SH, Pitzer VE. Asymptomatic Transmission and the Infection Fatality Risk for COVID-19: Implications for School Reopening. *Clin Infect Dis.* (2021) 72(9):1493-1496. doi: 10.1093/cid/ciaa855
3. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA.* (2020) 323(18):1775-1776. doi: 10.1001/jama.2020.4683.
4. Available on <https://covid19.who.int/>.
5. Frederiksen LSF, Zhang Y, Foged C, Thakur A. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. *Front Immunol.* (2020) 11:1817. doi: 10.3389/fimmu.2020.01817
6. Lundstrom K. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. *Viruses.* (2020) 12(11):1324. doi: 10.3390/v12111324
7. Lundstrom K. Viral Vectors for COVID-19 Vaccine Development. *Viruses.* (2021) 13(2):317. doi: 10.3390/v13020317
8. Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. *Vaccines (Basel)* (2021) 9(2):147. doi: 10.3390/vaccines9020147
9. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. *Nat Rev Drug Discov.* (2018) 17(4):261-279. doi: 10.1038/nrd.2017.243
10. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID-19 vaccine safety. *Int J Mol Med* (2020) 46(5):1599-1602. doi: 10.3892/ijmm.2020.4733
11. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, Alghamdi BS, Alahmadi AA, Hassan NA, Sindi N, Alghamdi SA, Almohaimeed HM, Mohammedsaleh ZM, Al-Shaikh TM, Almuhayawi MS, Ali SS, El-Hamamsy M. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. *Int J Gen Med.* (2021) 14:1389-1401. doi: 10.2147/IJGM.S310497

12. Mahase E. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA. *BMJ*. (2021) 373:n1046. doi: 10.1136/bmj.n1046.
13. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med*. (2021) 384(22):2092-2101. doi: 10.1056/NEJMoa2104840.
14. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med*. (2021) 384(23):2202-2211. doi: 10.1056/NEJMoa210538
15. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med*. 2021 Jun 3;384(22):2124-2130. doi: 10.1056/NEJMoa2104882
16. Helms JM, Ansteatt KT, Roberts JC, Kamatam S, Foong KS, Labayog JS, Tarantino MD. Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. *J Blood Med*. 2021 Apr 6;12:221-224. doi: 10.2147/JBM.S307047
17. Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine. *Cureus*. (2021) 13(3):e14099. doi: 10.7759/cureus.14099
18. Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. *Tidsskr Nor Laegeforen*. (2021) 29;141. English, Norwegian. doi: 10.4045/tidsskr.21.0312
19. Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, Bussel JB. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. *Am J Hematol*. (2021) 1;96(5):534-537. doi: 10.1002/ajh.26132.
20. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. *JAMA* (2021) 30:e217517. doi: 10.1001/jama.2021.7517
21. Blauenfeldt RA, Kristensen SR, Ernstsens SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. *J Thromb Haemost*. (2021) doi: 10.1111/jth.15347
22. Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, Donnerstag FG, Weißenborn K, Höglinger GU, Maasoumy B, Wedemeyer H, Ganser A. Prothrombotic immune thrombocytopenia after COVID-19 vaccine. *Blood* (2021) blood.2021011958. doi: 10.1182/blood.2021011958.
23. McGonagle D, De Marco G, Bridgwood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. *J Autoimmun*. (2021) 121:102662.
24. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. *Heparin-Induced Thrombocytopenia*. 4th edition. Informa Healthcare USA; New York: 2007. p. 21-66

25. Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. *Blood*. (1997) 89(2):370-5.
26. Kasthuri RS, Glover SL, Jonas W, McEachron T, Pawlinski R, Arepally GM, Key NS, Mackman N. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. *Blood*. (2012) 119(22):5285-93. doi: 10.1182/blood-2011-06-359430.
27. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. *Blood*. (1994) 84(11):3691-9.
28. Jaax ME, Greinacher A. Management of heparin-induced thrombocytopenia. *Expert Opin Pharmacother*. (2012) 13(7):987-1006. doi: 10.1517/14656566.2012.678834.
29. A. Greinacher, et al., Towards understanding ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT), *Res. Sq.* (2021), <https://doi.org/10.21203/rs.3.rs-440461/v1>
30. Mitra I, Nair NK, Mishra PK. Nucleic acids in circulation: are they harmful to the host? *J Biosci*. (2012) 37(2):301-12. doi: 10.1007/s12038-012-9192-8
31. Lande R, Lee EY, Palazzo R, Marinari B, Pietraforte I, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. *Nat Commun*. (2019) 10(1):1731. doi: 10.1038/s41467-019-09683-z.
32. Jaax ME, Krauel K, Marschall T, Brandt S, Gansler J, Fürll B, Appel B, Fischer S, Block S, Helm CA, Müller S, Preissner KT, Greinacher A. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. *Blood* (2013) 122(2):272-81
33. Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YM. Time course of early and late changes in plasma DNA in trauma patients. *Clin Chem*. (2003) 49(8):1286-91
34. Kikuchi Y, Rykova EY, eds. Extracellular Nucleic Acids. In: Gross HJ, Bujnicki JM, eds. *Nucleic Acids and Molecular Biology*. Vol 25. Berlin: Springer-Verlag; 2010.
35. Moores G, Warkentin TE, Farooqi MAM, Jevtic SD, Zeller MP, Perera KS. Spontaneous heparin-induced thrombocytopenia presenting as cerebral venous sinus thrombosis. *Neurology Clinical Practice*. (2020). doi: 10.1212/CPJ.0000000000000805
36. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. *Am J Med* (2008) 121: 632-6
37. Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT? *J Thromb Haemost* (2008) 6: 1598-600
38. Pruthi RK, Daniels PR, Nambudiri GS, Warkentin TE. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: A second example of postorthopedic surgery ‘spontaneous’ HIT. *J Thromb Haemost* (2009) 7:499–501
39. Ketha S, Smithedajkul P, Vella A, Pruthi R, Wysokinski W, McBane R. Adrenal haemorrhage due to heparin-induced thrombocytopenia. *Thromb Haemost* (2013) 109:669–675
40. Hwang SR, Wang Y, Weil EL, Padmanabhan A, Warkentin TE, Pruthi RK. Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. *Platelets* (2020) 1:1-5. doi: 10.1080/09537104.2020

41. Eric Kowarz, Lea Krutzke, Jenny Reis et al. "Vaccine-Induced Covid-19 Mimicry" Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines. (2021) PREPRINT (Version 1) available at Research Square [<https://doi.org/10.21203/rs.3.rs-558954/v1>].
42. Kashir J, Ambia AR, Shafqat A, Sajid MR, AlKattan K, Yaqinuddin A. Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT). *J Leukoc Biol.* (2021). doi: 10.1002/JLB.5COVR0621-320RR.
43. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. *J Exp Med.* (2020) 217(6).
44. Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. *Semin Thromb Hemost.* (2019) 45:86-93.
45. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med.* (2010) 16:887-896.
46. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. *Blood.* (2011) 118:3708-3714.
47. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci U S A.* (2010) 107:15880-15885.
48. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. *Blood.* (2014) 123:2768-2776
49. Maugeri N, Campana L, Gavina M, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. *J Thromb Haemost.* (2014) 12:2074-2088.
50. Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin promotes neutrophil extracellular trap formation in mice. *Blood.* (2015) 126:242-246.
51. Demento SL, Eisenbarth SC, Foellmer HG, et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. *Vaccine.* (2009) 27:3013-3021.
52. Reinke S, Thakur A, Gartlan C, Bezbradica JS, Milicic A. Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants. *Vaccines (Basel).* (2020) 8(3):554. doi: 10.3390/vaccines8030554
53. Zheng Y, Wang AW, Yu M, et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. *Blood* (2014) 123:931–934
54. Krauel K, Schulze A, Jouni R, et al. Further insights into the anti-PF4/heparin IgM immune response. *Thromb Haemost* (2015) 115:752–761
55. Zheng Y, Yu M, Padmanabhan A, et al. Critical role of CD4 T cells in PF4/heparin antibody production in mice. *Blood* (2015) 125:1826–1829
56. Karnes JH, Cronin RM, Rollin J, et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. *Thromb Haemost* (2015) 113:772–781
57. Rollin J, Pouplard C, Sung HC, et al. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. *Blood* (2015) 125:2397–2404
58. Padmanabhan A. Why 'R' HIT patients predisposed to thrombosis? *Blood* (2015) 125:2319–2320
59. Tutwiler V, Madeeva D, Ahn HS, et al. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. *Blood* (2016) 127:464–472

60. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med.* (2001) 344(17):1286-92. doi: 10.1056/NEJM200104263441704
61. Selleng K, Schutt A, Selleng S, et al. Studies of the anti-platelet factor 4/ heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. *Transfusion* (2010) 50:32-9
62. Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. *N Engl J Med* (2015) 372:492– 494. Examples of ‘autoimmune-like’ HIT presenting as bilateral adrenal hemorrhages; one patient had ‘delayed-onset’ HIT and the other ‘spontaneous HIT syndrome’
63. Jaafar J, Boehlen F, Philippe J, Nendaz M. Restoration of adrenal function after bilateral adrenal damage due to heparin-induced thrombocytopenia (HIT): a case report. *J Med Case Rep.* (2015) 3;9:18. doi: 10.1186/1752-1947-9-18
64. Stavridis GT, Vasili M, Ashrafian H, Athanasiou T, Melissari E, Manginas A. Trans-aortic endoscopic ventricular thrombectomy in a patient with HIT and concomitant Aortic and ventricular thromboses. *Gen Thorac Cardiovasc Surg.* (2016) 64(10):621-4. doi: 10.1007/s11748-015-0540-0
65. Altoijry A, MacKenzie KS, Corriveau MM, et al. Heparin-induced thrombocytopenia causing graft thrombosis and bowel ischemia postendovascular aneurysm repair. *J Vasc Surg* (2015) 61:234–236
66. Campisi S, Fuzellier JF, Vola M, Favre JP. Giant left ventricular thrombus formation associated with heparin-induced thrombocytopenia. *Ann Thorac Surg.* (2014) 98(6):e143-5. doi: 10.1016/j.athoracsur.2014.08.054.
67. Pandey S, Drobena G, Cottler-Fox M. TRANSFUSION MEDICINE ILLUSTRATED. Heparin-induced thrombocytopenia: a cautionary tale. *Transfusion.* (2015) 55(12):2790. doi: 10.1111/trf.13297
68. Warkentin TE. Heparin-induced thrombocytopenia. *Curr Opin Crit Care* (2015) 21:576–585. doi: 10.1097/MCC.0000000000000259
69. Fawaz B, Candelario NM, Rochet N, Tran C, Brau C. Warfarin-induced skin necrosis following heparin-induced thrombocytopenia. *Proc (Bayl Univ Med Cent).* (2016) 29(1):60-1. doi: 10.1080/08998280.2016.11929362.
70. Piazza G. Cerebral venous thrombosis. *Circulation.* (2012) 125(13):1704-1709. doi:10.1161/CIRCULATIONAHA.111.067835.
71. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* (2011) 42(4):1158-1192. doi:10.1161/STR.0b013e31820a8364.
72. Silvis SM, Aguiar de Sousa D, Ferro JM, Coutinho JM. Cerebral venous thrombosis. *Nat Rev Neurol.* (2017) 13(9):555-565. doi:10.1038/nrneurol.2017.104.
73. Furie KL, Cushman M, Elkind MSV, Lyden PD, Saposnik G; American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. *Stroke.* (2021) 52(7): 2478-2482. doi:10.1161/STROKEAHA.121.035564.

74. Idiculla PS, Gurala D, PalanisamyM, Vijayakumar R, Dhandapani S, Nagarajan E. Cerebral venous thrombosis: a comprehensive review. *Eur Neurol.* (2020) 83(4):369-379. doi:10.1159/000509802.
75. Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. *BMJ Case Rep.* (2021) 14(7):e243975. doi: 10.1136/bcr-2021-243975.
76. Rizk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G, Lavie CJ. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. *JAMA Cardiol.* (2021). doi: 10.1001/jamacardio.2021.3444.
77. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. *Lancet.* (1991) 338(8767):597-600. doi:10.1016/0140-6736(91)90607-Q.
78. de Bruijn SFTM, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. *Stroke.* (1999) 30(3):484-488. doi:10.1161/01.STR.30.3.484.
79. von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors. *Thromb Haemost.* (2021). doi: 10.1055/a-1481-3039.
80. Lee D, Warkentin T. Frequency of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A, editors. *Heparin-Induced Thrombocytopenia*. 4th edition. Informa Healthcare; New York: 2007. p. 67-116
81. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. *J Thromb Haemost* (2004) 2:2133-7
82. Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. *Blood* (2011) 117:1370-8
83. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* (2012) 141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303
84. Watson H, Davidson S, Keeling D; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. *Br J Haematol* (2012) 159: 528-40

Figures captions:

Figure 1: PRISMA Flow Diagram;

Figure 2: Autoptic findings;

Figure 3: Thrombosis location;

Figure 4: Patient medical history;

Figure 5: Time from vaccination to admission (days);

Figure 6: Onset of symptoms from vaccination;

Figure 7: Signs and symptoms at admission;

Figure 8: Treatment administration.

Tables captions:

Table 1: Analyzed studies;

Table 2: Laboratory data (Platelet count and Fibrinogen);

Table 3: PF-4 antibodies value (ELISA);

Table 4: Patients demographic;

Table 5: Time from vaccination;

Table 6: Onset of symptoms from vaccination;

Table 7: Outcome.

Article	Sample size	Vaccine type	Age / Age Range (years)	Female (%)	Mean Platelet count	PF4 positivity (%)	Major Intracranial Haemorrhage (%)	Cerebral venous sinus thrombosis (%)	Headaches at admission (%)	Heparin treatment (%)	Platelet transfusion (%)	Death (%)	Time/Mean Time from vaccination to admission (days)	Onset of symptoms from vaccination (days/mean days)
Greinacher A. et al 2021	11	Astrazeneca	22-49	18%	35300.0	100%	9%	82%	-	36%	0%	55%	-	9.27
Scully M. et al 2021	23	Astrazeneca	21-77	61%	45227.3	93%	17%	57%	-	-	-	30%	12.43	-
Schultz N. H. Et al 2021	5	Astrazeneca	32-54	80%	27000.0	100%	-	80%	80%	20%	100%	60%	8.40	-
Helms J. M. Et al 2021	1	Moderna	74	0%	-	-	-	-	0%	0%	100%	0%	1	1
Malayala S. V. et al 2021	1	Moderna	60	0%	-	-	-	-	0%	-	-	0%	2	2
Bjørnstad-Tuveng T. H. et al 2021	1	Astrazeneca	30-39	100%	37000.0	100%	100%	100%	83%	0%	0%	100%	7.00	7-00
Lee E. J. et al 2021	1	Pfizer	22	0%	-	-	-	-	0%	0%	100%	0%	3	3
See I. et al 2021	12	Astrazeneca	18-40	-	45750.0	100%	-	100%	-	-	-	25%	16.06	8.83
Blauenfeldt R. A. et al 2021	1	Astrazeneca	60	100%	5000.0	100%	-	-	-	0%	100%	100%	7.00	1.00
Tiede et al 2021	5	Astrazeneca	41-67	100%	49200.0	100%	-	20%	80%	20%	40%	-	8.40	-

Table 2: Laboratory data (Platelet count and Fibrinogen)

	Mean platelet	S.E.P.	Mean Fibrinogen	S.E.F.	S.E.F.
Blauenfeldt R. A. et al 2021	5000.0		374.0		1
Greinacher A. et al 2021	35300.0	10210.9	191.5	58.9	11
Bjørnstad-Tuveng T. H. et al 2021	37000.0		220.00		1
Schultz N. H. et al 2021	27000.0	10945.3	152.0	28.9	5
Scully M. et al 2021	45227.3	6788.1	187.8	25.0	23
See I. et al 2021	45750.0	12252.5	159.3	23.6	12
Tiede A. et al 2021	49200.0	16184.6			5

Table 3: PF-4 antibodies value (ELISA)

	Negative	Positive	NA	Size
Blauenfeldt R. A. et al 2021	0.00	1.00	0	1
Greinacher A. et al 2021	0.00	1.00	2	11
Bjørnstad-Tuveng T. H. et al 2021	0.00	1.00	0	1
Schultz N. H. et al 2021	0.00	1.00	0	5
Scully M. et al 2021	0.00	1.00	8	23
See I. et al 2021	0.00	1.00	1	12
Tiede A. et al 2021	0.00	1.00	0	5

Table 4: Patients demographic

	Range Age	Male	Female	Gender NA	Size
Blauenfeldt R. A. et al 2021	60	0	1	0	1
Greinacher A. et al 2021	22-49	9	2	0	11
Bjørnstad-Tuveng T. H. et al 2021	30-39	0	1	0	1
Schultz N. H. et al 2021	32-54	1	4	0	5
Scully M. et al 2021	21-77	9	14	0	23
See I. et al 2021	18-40+			12	12
Tiede A. et al 2021	41-67	0	5	0	5

Table 5: Time from vaccination

	Mean	S.E.	Size
Blauenfeldt R. A. et al 2021	7.00		1
Greinacher A. et al 2021			2
Bjørnstad-Tuveng T. H. et al 2021	7.00		1
Schultz N. H. et al 2021	8.40	0.68	4
Scully M. et al 2021	12.43	0.82	14
See I. et al 2021	16.08	1.33	12
Tiede A. et al 2021	8.40	0.98	5

Table 6: Onset of symptoms from vaccination

	Mean day	S.E.	Size
Blauenfeldt R. A. et al 2021	1.00		1
Greinacher A. et al 2021	9.27	1.01	2
Bjørnstad-Tuveng T. H. et al 2021	7.00		1
Schultz N. H. et al 2021			4
Scully M. et al 2021			14
See I. et al 2021	8.83	0.84	12
Tiede A. et al 2021			5

Table 7: Outcome

	Alive	Death	Size
Blauenfeldt R. A. et al 2021	0.00	1.00	1
Greinacher A. et al 2021	0.40	0.60	2
Bjørnstad-Tuveng T. H. et al 2021	0.00	1.00	1
Schultz N. H. et al 2021	0.40	0.60	4
Scully M. et al 2021	0.70	0.30	14



PRISMA 2009 Flow Diagram




Figure 2.TIFF




Figure 5.TIF




Figure 5: Time from vaccination to admission(days)

Figure 6.TIF




Figure 6: Onset of symptoms from vaccination

